Limits...
Treatment of pediatric pulmonary hypertension.

Hawkins A, Tulloh R - Vasc Health Risk Manag (2009)

Bottom Line: We have a better understanding of the pathological process and have a range of medication which is starting to be able to palliate this previously fatal condition.This review describes the areas that are known in this condition and those that are less familiar.The histopathologic process and the various diagnostic tools are described and are followed by the current and future therapy at our disposal.

View Article: PubMed Central - PubMed

Affiliation: Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK.

ABSTRACT
Pulmonary hypertension was once thought to be a rare condition and only managed in specialized centers. Now however, with the advent of echocardiography, it is found in many clinical scenarios, in the neonate with chronic lung disease, in the acute setting in the intensive care unit, in connective tissue disease and in cardiology pre- and postoperatively. We have a better understanding of the pathological process and have a range of medication which is starting to be able to palliate this previously fatal condition. This review describes the areas that are known in this condition and those that are less familiar. The basic physiology behind pulmonary hypertension and pulmonary vascular disease is explained. The histopathologic process and the various diagnostic tools are described and are followed by the current and future therapy at our disposal.

Show MeSH

Related in: MedlinePlus

Meta-analysis of active treatment versus placebo in trials of current management strategies in pulmonary arterial hypertension.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2697585&req=5

f2-vhrm-5-509: Meta-analysis of active treatment versus placebo in trials of current management strategies in pulmonary arterial hypertension.

Mentions: A recent meta-analysis of trials of modern treatment modalities including phosphodiesterase inhibitors, endothelin receptor antagonists and prostacyclin agonists found that overall, active treatment resulted in reduction in mortality of 43% (risk ratio 0.57, 95% confidence interval [CI] 0.35–0.92; p = 0.023) (Figure 2).149


Treatment of pediatric pulmonary hypertension.

Hawkins A, Tulloh R - Vasc Health Risk Manag (2009)

Meta-analysis of active treatment versus placebo in trials of current management strategies in pulmonary arterial hypertension.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2697585&req=5

f2-vhrm-5-509: Meta-analysis of active treatment versus placebo in trials of current management strategies in pulmonary arterial hypertension.
Mentions: A recent meta-analysis of trials of modern treatment modalities including phosphodiesterase inhibitors, endothelin receptor antagonists and prostacyclin agonists found that overall, active treatment resulted in reduction in mortality of 43% (risk ratio 0.57, 95% confidence interval [CI] 0.35–0.92; p = 0.023) (Figure 2).149

Bottom Line: We have a better understanding of the pathological process and have a range of medication which is starting to be able to palliate this previously fatal condition.This review describes the areas that are known in this condition and those that are less familiar.The histopathologic process and the various diagnostic tools are described and are followed by the current and future therapy at our disposal.

View Article: PubMed Central - PubMed

Affiliation: Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK.

ABSTRACT
Pulmonary hypertension was once thought to be a rare condition and only managed in specialized centers. Now however, with the advent of echocardiography, it is found in many clinical scenarios, in the neonate with chronic lung disease, in the acute setting in the intensive care unit, in connective tissue disease and in cardiology pre- and postoperatively. We have a better understanding of the pathological process and have a range of medication which is starting to be able to palliate this previously fatal condition. This review describes the areas that are known in this condition and those that are less familiar. The basic physiology behind pulmonary hypertension and pulmonary vascular disease is explained. The histopathologic process and the various diagnostic tools are described and are followed by the current and future therapy at our disposal.

Show MeSH
Related in: MedlinePlus